LLY
ELI LILLY & CoPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 9 to Feb 13 ▼ 2 sells: David Taylor, Angus King sold $1,001 - $15,000, last disclosed Mar 24
- May 6 ▼ 1 insider sell $15.8M at $995.36
- Jun 2 to Jun 10 ▲ 2 buys: Ro Khanna, Gilbert Cisneros bought, last disclosed Jul 8
- Jun 10 ▼ 1 insider sell $2.9M at $1,150.77
- Jun 30 ▲ 6 funds open new positions (13F)
- Jul 1 to Jul 10 ▼ 2 sells: Michael Rulli, Dan Newhouse sold $1,001 - $15,000, last disclosed Aug 10
- Jul 30 to Aug 7 3 court rulings: Eli Lilly and Company v. Empower Clinic Services, LLC; Eli Lilly And Company v. Revive RX, LLC and 1 more
- Aug 5 ▲ Lilly reported Q2 2026 revenue of $22.97B (up 48% YoY, 11% above con…
- Aug 7 to Aug 17 ▼ 3 days of insider sells: $16.0M by 3 insiders, avg $1,182.09
- Aug 14 ▲ Short interest falls 28.0% to 6.56M
- Oct 14 Trial readout: Results Pending: Orforglipron (Phase 3), Completed 85d ago
- Nov 2 ▼ 1 insider sell $7.0M at $1,402.52
- Nov 16 New catalyst: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersBEARISH
5 insiders sold $41.6M.
- InstitutionsMIXED
Q2 2026: 55 added (6 new), 38 trimmed or exited. Largest new: Castle Hook Partners $558.0M, Meitav Investment House $143.1M.
- AnalystsBULLISH
32 of 37 rate it Buy or better. Median target $1,570.00 (+9%).
- Short sellersSTEADY
Short interest +3.6% to 7.21M shares. 2.7 days to cover, ≈0.8% of shares.
- TrendUPTREND
15% above its 50-day average. New closing high $1,443.50 on Nov 13.
- SocialQUIET
Crowd 83° (bullish) this week from 11 mentions: 10 bullish, 0 bearish. No setup is alerting. Excludes 1 subscriber-only day.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| AMERICAN CENTURY COMPANIES INC | ADD | $2.8B |
| BARCLAYS PLC | TRIM | $1.4B |
| CITADEL ADVISORS LLC | DOUBLED | $1.1B |
| POLEN CAPITAL MANAGEMENT LLC | TRIM | $799.9M |
| Quantinno Capital Management LP | ADD | $656.7M |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | DOUBLED | $631.1M |
| PARNASSUS INVESTMENTS, LLC | TRIM | $630.3M |
| Assenagon Asset Management S.A. | TRIM | $600.9M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
37 analystsPrice is inside the target range. Median implies +9%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 16, 2026 | 🔒 Fresh data, subscribers only MAINTAIN | |
| Nov 9, 2026 | Jefferies MAINTAIN | Buy |
| Nov 2, 2026 | Cantor Fitzgerald MAINTAIN | Overweight |
| Oct 30, 2026 | UBS MAINTAIN | Buy |
| Oct 30, 2026 | JP Morgan MAINTAIN | Overweight |
| Oct 30, 2026 | Citigroup MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Jonsson Patrik EVP & President, LLY Int'l Nov 10, 2026 | GIFT | 704 sh |
Ricks David A President, Chair, and CEO Nov 3, 2026 | GIFT | 23,538 sh |
Skovronsky Daniel EVP, CS&PO & Pres. LRL Nov 2, 2026 | GIFT | 119 sh |
Hakim Anat EVP, GC & Secretary Nov 2, 2026 | SELL | $7.0M |
Dozier Eric EVP, Chief People Officer Nov 1, 2026 | EXERCISE | 2,300 sh |
Hernandez Edgardo EVP & Pres., Mfg. Operations Nov 1, 2026 | TAX W/H | $1.6M |
Custer Kenneth L. EVP & President, Card Met Hlth Nov 1, 2026 | TAX W/H | $2.0M |
Dozier Eric EVP, Chief People Officer Nov 1, 2026 | TAX W/H | $1.4M |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
22 filings · 1 press release · 6 bullish · 1 bearish · 15 neutral- NEUTRAL 144Oct 30, 2026
Lilly Endowment Inc., the company's largest shareholder with a $108.4B stake, filed a Form 144…
The endowment's consistent selling pattern suggests ongoing portfolio rebalancing rather than a negative view on Lilly. Monitor future Form 144 and Form 4 filings for any acceleration in selling…
- BULLISH 8-KOct 29, 2026
Lilly reported Q3 2026 revenue of $24.4B (+39% YoY) and non-GAAP EPS of $7.48 (+7% YoY), beating…
The revenue beat and raised guidance confirm strong demand for tirzepatide products (Mounjaro/Zepbound). Watch for the retatrutide BLA submission in Q1 2027 and the impact of NRDL pricing in China…
- NEUTRAL PRESS-RELEASEOct 26, 2026
Eli Lilly declared a Q4 2026 dividend of $1.73 per share, payable December 10, 2026, to…
Dividend unchanged, no signal for earnings or capital allocation shift. Monitor upcoming Q3 2026 earnings release for financial performance and guidance updates.
- NEUTRAL COURT-RULINGOct 26, 2026
Novo Nordisk sought a preliminary injunction against Eli Lilly over comparative advertising for…
The denial of the preliminary injunction allows Lilly to continue its comparative advertising campaign. The case will proceed to discovery and potentially trial; a final judgment on the merits could…
All LLY filing & press-release reports (23)
- 144 reportOct 30, 2026
- 8-K reportOct 29, 2026
- COURT-RULING reportOct 26, 2026
- PRESS-RELEASE reportOct 26, 2026
- SC 13G/A reportOct 19, 2026
- INST-CLUSTER reportOct 16, 2026
- PRESS-RELEASE reportOct 15, 2026
- 144 reportOct 7, 2026
- PRESS-RELEASE reportSep 11, 2026
- COURT-RULING reportSep 8, 2026
- CLUSTER reportAug 18, 2026
- CLUSTER reportAug 11, 2026
- COURT-RULING reportAug 7, 2026
- COURT-RULING reportAug 4, 2026
- 8-K reportAug 5, 2026
- COURT-RULING reportJul 31, 2026
- COURT-RULING reportJul 30, 2026
- PRESS-RELEASE reportJul 22, 2026
- COURT-RULING reportJul 14, 2026
- COURT-RULING reportJul 13, 2026
- COURT-RULING reportApr 30, 2026
- COURT-RULING reportApr 16, 2026
- DEFA14A reportMar 20, 2026